308 related articles for article (PubMed ID: 28824054)
1. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
3. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
4. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
5. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy of long-acting somatostatin analog as adjunctive therapy in patients with active acromegaly].
Gołkowski F; Buziak-Bereza M; Huszno B
Przegl Lek; 2006; 63(3):117-22. PubMed ID: 16967698
[TBL] [Abstract][Full Text] [Related]
7. Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration.
Ozbek M; Erdogan M; Akbal E; Gönülalan G
Exp Clin Endocrinol Diabetes; 2009 Jul; 117(7):309-11. PubMed ID: 18841538
[TBL] [Abstract][Full Text] [Related]
8. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
Barakat S; Melmed S
Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
[TBL] [Abstract][Full Text] [Related]
9. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
10. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
11. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
12. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
13. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal.
Livadas S; Hadjidakis DJ; Argyropoulou MI; Stamatelatou M; Kelekis D; Raptis SA
Hormones (Athens); 2006; 5(1):57-63. PubMed ID: 16728386
[TBL] [Abstract][Full Text] [Related]
14. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
15. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
16. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
17. Improvement of acromegaly after octreotide LAR treatment.
Mangupli R; Lisette A; Ivett C; Paul C; de los Ríos Victoria C; Luis CJ
Pituitary; 2003; 6(1):29-34. PubMed ID: 14674721
[TBL] [Abstract][Full Text] [Related]
18. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
19. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
20. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
